PEA15

Astrocytic phosphoprotein PEA-15 ;
15 kDa phosphoprotein enriched in astrocytes ;
Phosphoprotein enriched in diabetes ;
PED ;

function:Blocks Ras-mediated inhibition of integrin activation and modulates the ERK MAP kinase cascade. Inhibits RPS6KA3 activities by retaining it in the cytoplasm (By similarity). Inhibits both TNFRSF6- and TNFRSF1A-mediated CASP8 activity and apoptosis. Regulates glucose transport by controlling both the content of SLC2A1 glucose transporters on the plasma membrane and the insulin-dependent trafficking of SLC2A4 from the cell interior to the surface.,PTM:Phosphorylated by protein kinase C and calcium-calmodulin-dependent protein kinase. These phosphorylation events are modulated by neurotransmitters or hormones.,similarity:Contains 1 DED (death effector) domain.,subcellular location:Associated with microtubules.,subunit:Binds RPS6KA3, MAPK3 and MAPK1. Transient interaction with PLD1 and PLD2 (By similarity). Interacts with CASP8 and FADD.,tissue specificity:Ubiquitously expressed. Most abundant in tissues such as heart, brain, muscle and adipose tissue which utilize glucose as an energy source. Lower expression in glucose-producing tissues. Higher levels of expression are found in tissues from individuals with type 2 diabetes than in controls.,

apoptosis, anti-apoptosis, cell death, carbohydrate transport, regulation of glucose transport, negative regulation of glucose transport, regulation of cell death, programmed cell death, death, regulation of apoptosis, negative regulation of apoptosis, regulation of programmed cell death, negative regulation of programmed cell death, regulation of glucose import, negative regulation of glucose import, negative regulation of transport, negative regulation of cell death,

Cytoplasm. Associated with microtubules.

Ubiquitously expressed. Most abundant in tissues such as heart, brain, muscle and adipose tissue which utilize glucose as an energy source. Lower expression in glucose-producing tissues. Higher levels of expression are found in tissues from individuals with type 2 diabetes than in controls.